Health ❯ Healthcare ❯ Cancer Treatment

Targeted Therapy

EGFR Inhibitors Antibody Drug Conjugates NSD2 Inhibition HER2 Mutations Bispecific Antibodies Zongertinib Research Innovations KRAS G12C Inhibitors RSPO2 Inhibition Small Molecule Therapy Encorafenib and Cetuximab Epigenetic Therapy Antibody-Drug Conjugates HER2-targeting Drugs Triple-Negative Breast Cancer FLT3-ITD Mutation CAR-T Cell Therapy Belantamab Mafodotin CDK12 Inhibitors Bruton’s Tyrosine Kinase Inhibitors Encorafenib and Binimetinib NY-ESO-1 Antigen Nectin-4 Therapies BTK Inhibitors EGFR Inhibition Tyrosine Kinase Inhibitors Tumor Suppressors EGFR Tyrosine Kinase Inhibitors Dual Targeting Osimertinib Integrin Beta-6 (IB6) Inhibition Dual Gene Targeting EGFR-Mutated NSCLC Cabozantinib Glycan-Dependent Therapies Extracellular Matrix EGFR-Tyrosine Kinase Inhibitors Aumolertinib NRF2 Inhibitors Datopotamab Deruxtecan Viral Mimics Fibroblast Activation Protein siRNA Therapy CAR T Cell Therapy PARP Inhibitors KRAS Mutations PI3Kα Inhibitors Protein Therapy HER2+ Therapy Her2 Positive Breast Cancer Menin Inhibitors Alectinib vs Crizotinib PIK3CA Mutations Trastuzumab Deruxtecan (T-DXd) MEK Inhibitors CD33-Targeted Therapies T-DXd (Enhertu) HER2-Positive Therapy CD123-Targeting Therapies Natural Killer Cells Combination Therapy XPO1 Protein

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Results presented at SABCS, published in JCO, show a clinically meaningful delay in progression with first-line maintenance tucatinib.

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

Shorter, Chemo-Free Strategies Match or Beat Standard Care in Adult Leukemias at ASH

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

Engineered CAR-T Cells Target PD-L1 to Deliver IL-12 at Tumors, Showing Solid-Tumor Gains in Mice

Glycan-Targeting ‘GlyTR’ Therapy Kills Diverse Cancers in Preclinical Tests

FDA Grants Priority Review for Enhertu Plus Pertuzumab in First-Line HER2-Positive Metastatic Breast Cancer

Preclinical PET Tracer Enables Same-Day Imaging of Nectin-4 in Breast and Bladder Cancers

FAP-Targeted Radioligand Yields Near-Complete Response in Three Solitary Fibrous Tumor Patients

Lung Tumors Reprogram Bone Marrow Progenitors as NRF2 Emerges as a Target

WCLC 2025: Combination Approaches Redraw EGFR-Mutant NSCLC Care

Iza-Bren Plus Osimertinib Delivers 100% Response in Small First-Line EGFR-Mutant NSCLC Cohort

UNC Researchers Unveil Dual-Silencing RNAi Boosting Tumor Cell Killing Forty-Fold

Preclinical Studies Confirm NKAPL as Lung Cancer Tumor Suppressor, Prompt Demethylation Therapy Development

Nagoya University Advances Eva1-Targeted CAR-T Therapy to Preclinical Safety Testing

Triplet Therapy Doubles Survival in BRAF V600E Metastatic Colorectal Cancer

Key Molecular Target Identified in Fatal Childhood Brain Cancer